Biotech Esperion Therapeutics sets terms for $63 million IPO

By
A A A
Share |

Esperion Therapeutics, a biotech focused on developing a treatment for patients with elevated levels of low-density lipoprotein cholesterol, announced terms for its IPO on Wednesday. The Plymouth, MI-based company plans to raise $63 million by offering 4.5 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Esperion Therapeutics would command a market value of $197 million.

Esperion Therapeutics, which was founded in 1998, plans to list on the NASDAQ under the symbol ESPR. Esperion Therapeutics initially filed confidentially in April 2013. Credit Suisse and Citi are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ESPR

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

72,157,294
  • $61.36 ▼ 2.65%
56,535,455
  • $34.92 ▼ 3.78%
49,608,479
  • $4.42 ▼ 3.07%
49,328,445
  • $25.91 ▼ 3.18%
48,932,529
  • $16.37 ▲ 0.49%
38,182,422
  • $3.17 ▼ 1.55%
33,297,581
  • $73.86 ▲ 1.37%
32,790,375
  • $47.43 ▼ 1.02%
As of 4/23/2014, 04:07 PM